Home / People / Jane Hollywood
Jane Hollywood

Jane Hollywood

Patent Attorney

T +44 20 7067 3342
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
United Kingdom
Languages English

Jane is a Partner, UK Chartered Patent Attorney and European Patent Attorney. She is a Life Science specialist working with companies to obtain patent protection and providing advice on all aspects of patent strategy. Jane is also experienced in opposition and appeal proceedings before the European Patent Office, where she has represented clients across a range of life science technologies, most notably in relation to biologics, formulations and genetic engineering.  

In the transgenic field, Jane has worked for many years with Kymab, handling drafting, multi-jurisdictional patent prosecution and opposition matters at the European Patent Office.  This subject matter is of great technical complexity, relating to the technology underlying Kymab’s transgenic mouse platform including gene editing techniques. These cases are coordinated alongside national litigation relevant to Kymab’s antibody discovery platform. Jane also has extensive experience in the cell therapy sector having represented companies such as Athersys and International Stem Cell Corporation in relation to obtaining patent protection for their products.

This experience has led to Jane having a particular interest in genetic engineering technologies and their application in gene and cell therapies, sustainable food technologies and agriculture and she works with both established and start-up companies in these areas. With a PhD in plant sciences, she also works with companies in the burgeoning cannabis sector providing strategy advice and assisting them in navigating the complex situation at the European Patent Office to successfully obtain patent protection.

more less

“Biotech specialist Hollywood is also one to watch, thanks to the foothold she is carving in burgeoning fields such as plant sciences and the nascent cannabis industry.”

IAM Patent 1000, 2020


  • 2008 – European and UK Patent Attorney
  • 2003 – PhD, UCL, London
  • 2000 – BSc Biology, University of Bristol
more less


Show only
24 September 2019
AI in dia­gnos­is – pat­ent pro­tec­tion
In this art­icle, we take a closer look at pat­ent pro­tec­tion in Europe for de­vel­op­ments of AI in dia­gnost­ic ap­plic­a­tions. There is enorm­ous po­ten­tial for the use of AI in dia­gnos­is and this is re­flec­ted in the in­creas­ing num­ber of reg­u­lat­ory ap­provals bein
20 April 2020
CMS Ex­pert Guide to can­nabis law and le­gis­la­tion
Are you look­ing for in­form­a­tion on can­nabis law and le­gis­la­tion? This CMS Ex­pert Guide provides you with everything you need to know.
14 September 2020
An EPO Case Law Round-Up: Ad­ded Mat­ter
The EPO is well-known for its strict ap­proach to as­sess­ing amend­ments un­der the ad­ded mat­ter pro­vi­sion of Art­icle 123 of the European Pat­ent Con­ven­tion. This of­ten cre­ates com­plex leg­al scen­ari­os which...
13 August 2020
Sus­tain­able food pro­gress may close glob­al reg­u­lat­ory gap
In­nov­a­tion in the sus­tain­able food sec­tor is for­ging ahead at a re­mark­able pace. Our cur­rent food sources ac­count for nearly one-third of glob­al GHG emis­sions while con­sumers are in­creas­ingly bet­ter edu­cated...
19 May 2020
Not Pat­entable – The end of the line for plants and an­im­als pro­duced by...
The highest ju­di­cial au­thor­ity at the EPO is­sued their opin­ion late last week in the con­tro­ver­sial G3/19 (Pep­per) case. Con­trary to pre­vi­ous de­cisions in G2/12 and G2/13 (To­mato/Broc­coli), the En­larged...
15 January 2020
Can newly dis­covered can­nabis com­pounds be pro­tec­ted by pat­ents?
A break­through dis­cov­ery has re­cently hit the news: tet­rahy­drocan­nabi­phorol (THCP) and can­na­bid­i­phorol (CB­DP), two new can­nabin­oid com­pounds, have been dis­covered in Can­nabis sativa and char­ac­ter­ised...
17 December 2019
The rise of pat­ent wars in Europe’s gene ther­apy space
The gene ther­apy in­dustry is in an ex­cit­ing phase of growth, un­der­go­ing sig­ni­fic­ant M&A activ­ity, product sales and new mar­ket­ing au­thor­isa­tions that are be­ing is­sued with in­creas­ing reg­u­lar­ity glob­ally....
13 June 2019
SPC Man­u­fac­tur­ing Waiver to come in­to ef­fect 1 Ju­ly 2019
Gen­er­ics com­pan­ies will soon be able to man­u­fac­ture SPC-pro­tec­ted drugs for ex­port out­side the EU un­der new man­u­fac­tur­ing waiver pro­vi­sions. In the last six months of the SPC life­time, it will also be...
30 May 2019
EPO's strict ap­proach to de­cid­ing if a com­pos­i­tion can be­ne­fit from med­ic­al...
The EPO Tech­nic­al Board of Ap­peal (TBA) re­viewed the law around nov­elty of use, and de­term­ined that in the case of Car­di­oPoly­mer, Inc.'s European pat­ent ap­plic­a­tion (EP07837908.8), the claimed chem­ic­al...